MedTrace Logo

Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)

NCT00336505 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 584

Last updated 2010-02-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the efficacy of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).

Conditions

Interventions

DRUG

Cethromycin

Cethromycin 300 mg once per day (QD) for 7 days, administered orally

DRUG

Clarithromycin

Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally

Sponsors & Collaborators

  • Advanced Life Sciences, Inc.

    lead INDUSTRY

Principal Investigators

  • David A. Eiznhamer, PhD · Advanced Life Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00336505 on ClinicalTrials.gov